RALEIGH, N.C., Mar 9, 2012 – Okyanos Heart Institute, which brings a new option, standard of care and quality of life to patients with coronary artery disease (CAD), has announced that Howard T. Walpole Jr., M.D., MBA, FACC, FACAI, will serve as the organization’s Chief Medical Officer and Interventional Cardiologist. Walpole is a prominent cardiologist in the United States who in his 25 years of practice as a patient-centric physician has completed approximately 5,000 catheter-based interventions and 12,000 diagnostic catheterizations, as well as myocardial biopsies.
Previously, Walpole served as the Chief of Cardiac Sciences at St. Thomas Hospital in Nashville, Tenn., a medical center with 3,300 employees and a service population of approximately 2 million across three states. He led the strategy and operations of the Cardiac Sciences division, which included 37 cardiologists, five cardiac surgeons and nine cardiac anesthesiologists. Prior to that, Walpole was the managing partner of The Heart Group, PLLC, where he directed an operating budget of more than $20 million and led the growth strategy which expanded the practice from seven cardiologists to 37 and developed 15 new clinic locations in middle Tennessee and southern Kentucky.
A longtime member of the American Heart Association, Walpole served two terms as the president of the Davidson County, Tennessee Chapter from 1996-1997 and 2009-2010. Besides his present duties on the board of trustees through 2017, his participation in the American College of Cardiology includes working on the board of governors chair-elect nominating committee, co-chairing the “Evolving Models of Clinical Practice” from 2009-2010 and chairing the “Cardiovascular Care Summit” for 2012. Walpole received his Bachelor of Science from the University of Georgia, his M.D. from the Medical College of Georgia and his MBA from the Goizueta School of Business at Emory University in Georgia.
“I am honored to serve Okyanos Heart Institute as it launches bringing a new standard of care and a better quality of life to patients with severe heart disease where bypass and stents are no longer viable treatment options,” said Walpole. “Our medical practices combined with innovative research offer promising advances in cardiac care. I look forward to letting more people know about the advances in medicine that Okyanos has planned for the future.”
About Okyanos Heart Institute: (Oh – key – AH – nos)
Based in Freeport, Grand Bahama, Okyanos Heart Institute’s mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease using cardiac stem cell therapy. Okyanos adheres to U.S. surgical center standards and is led by CEO Matt Feshbach and Chief Medical Officer Howard T. Walpole Jr., M.D., M.B.A., F.A.C.C., F.A.C.A.I. Okyanos Treatment utilizes a unique blend of stem and regenerative cells derived from one’s own adipose (fat) tissue. The cells, when placed into the heart via a minimally-invasive catheterization, stimulate the growth of new blood vessels, a process known as angiogenesis. Angiogenesis facilitates blood flow in the heart and supports intake and use of oxygen (as demonstrated in rigorous clinical trials such as the PRECISE trial). The literary name Okyanos, the Greek god of the river Okeanos, symbolizes restoration of blood flow.